$CVAT
Cavitation Technologies, Inc. Stock $cvat

$cvat Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000168316824006768 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$0.00	$652.0K	$1.363M
YoY Change		1153.85%	230.02%
Cost Of Revenue		$115.0K	$156.0K
YoY Change		139.58%	28.93%
Gross Profit		$537.0K	$1.207M
YoY Change		13325.0%	286.86%
Gross Profit Margin		82.36%	88.55%
Selling, General & Admin		$152.0K	$707.0K
YoY Change		-52.94%	-40.69%
% of Gross Profit		28.31%	58.57%
Research & Development	$8.000K	$16.00K	$61.00K
YoY Change	-77.78%	433.33%	1933.33%
% of Gross Profit		2.98%	5.05%
Depreciation & Amortization		$0.00	$1.000K
YoY Change		-100.0%	-66.67%
% of Gross Profit		0.0%	0.08%
Operating Expenses	$8.000K	$168.0K	$769.0K
YoY Change	-96.8%	-48.47%	-35.81%
Operating Profit	-$226.0K	$369.0K	$438.0K
YoY Change	-9.6%	-214.6%	-149.44%
Interest Expense		$6.000K	-$1.000K
YoY Change		-100.54%	-116.67%
% of Operating Profit		1.63%	-0.23%
Other Income/Expense, Net
YoY Change
Pretax Income		$375.0K	$439.0K
YoY Change		-126.22%	-121.52%
Income Tax
% Of Pretax Income
Net Earnings	-$227.0K	$375.0K	$439.0K
YoY Change	-9.56%	-126.22%	-121.52%
Net Earnings / Revenue		57.52%	32.21%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	284.3M shares	284.3M shares	284.3M shares
Diluted Shares Outstanding	284.3M shares		284.3M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.000K	$179.0K
YoY Change	-98.57%	894.44%
Cash & Equivalents	$2.000K	$179.0K
Short-Term Investments
Other Short-Term Assets	$40.00K	$16.00K
YoY Change
Inventory
Prepaid Expenses	$40.00K	$16.00K
Receivables
Other Receivables
Total Short-Term Assets	$42.00K	$195.0K
YoY Change	-70.0%	983.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.00K	$0.00
YoY Change	2300.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Other Assets	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$35.00K	$53.00K
YoY Change	-67.29%	-57.6%
TOTAL ASSETS
Total Short-Term Assets	$42.00K	$195.0K
Total Long-Term Assets	$35.00K	$53.00K
Total Assets	$77.00K	$248.0K
YoY Change	-68.83%	73.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$187.0K	$129.0K
YoY Change	29.86%	7.5%
Accrued Expenses	$460.0K	$460.0K
YoY Change	16.75%	32.18%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.000K	$9.000K
YoY Change	80.0%	80.0%
Total Short-Term Liabilities	$656.0K	$598.0K
YoY Change	-47.01%	-30.79%
LONG-TERM LIABILITIES
Long-Term Debt	$128.0K	$130.0K
YoY Change	-11.72%	-10.34%
Other Long-Term Liabilities		$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$128.0K	$130.0K
YoY Change	-28.49%	-10.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$656.0K	$598.0K
Total Long-Term Liabilities	$128.0K	$130.0K
Total Liabilities	$784.0K	$728.0K
YoY Change	-44.67%	-31.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.07M	-$26.85M
YoY Change	-1.68%	-1.61%
Common Stock	$284.0K	$284.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$707.0K	-$480.0K
YoY Change
Total Liabilities & Shareholders Equity	$77.00K	$248.0K
YoY Change	-68.83%	73.43%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$227.0K	$375.0K	$439.0K
YoY Change	-9.56%	-126.22%	-121.52%
Depreciation, Depletion And Amortization		$0.00	$1.000K
YoY Change		-100.0%	-66.67%
Cash From Operating Activities	-$175.0K	$7.000K	$172.0K
YoY Change	-243.44%	-102.4%	-140.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.000K	-11.00K	-$11.00K
YoY Change
NET CHANGE
Cash From Operating Activities	-$175.0K	7.000K	$172.0K
Cash From Investing Activities
Cash From Financing Activities	-$2.000K	-11.00K	-$11.00K
Net Change In Cash	-$177.0K	-4.000K	$161.0K
YoY Change	-245.08%	-98.63%	-138.06%
FREE CASH FLOW
Cash From Operating Activities	-$175.0K	$7.000K	$172.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001376793
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	CVAT	Cashless Exercise Of Warrants CashlessExerciseOfWarrants		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	5474000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	284289740	shares
CY2024	dei	Auditor Firm AuditorFirmId	572
CY2024	dei	Auditor Name AuditorName	Weinberg & Company, P.A.
CY2024	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16000	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	195000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	18000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	113000	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	10000	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	10000	usd
CY2024Q2	us-gaap	Assets Assets	248000	usd
CY2023Q2	us-gaap	Assets Assets	143000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	129000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	120000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	414000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	280000	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	5000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	391000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	598000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	864000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	130000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	145000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	728000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1062000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	284289740	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	284289740	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	284289740	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	284289740	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	284000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	284000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26083000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26083000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26847000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27286000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-480000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-919000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	248000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143000	usd
CY2024	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	865000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	413000	usd
CY2024	CVAT	Revenue License Fee RevenueLicenseFee	498000	usd
CY2023	CVAT	Revenue License Fee RevenueLicenseFee	0	usd
CY2024	CVAT	Revenue Related Party RevenueRelatedParty	0	usd
CY2023	CVAT	Revenue Related Party RevenueRelatedParty	20000	usd
CY2024	us-gaap	Revenues Revenues	1363000	usd
CY2023	us-gaap	Revenues Revenues	433000	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	156000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	121000	usd
CY2024	us-gaap	Gross Profit GrossProfit	1207000	usd
CY2023	us-gaap	Gross Profit GrossProfit	312000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	708000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1195000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	769000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1198000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	438000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-886000	usd
CY2024	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1148000	usd
CY2024	us-gaap	Interest Expense InterestExpense	-1000	usd
CY2023	us-gaap	Interest Expense InterestExpense	6000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	439000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2040000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	284289740	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	284289740	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	281693701	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	281693701	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1036000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	85000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2040000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-919000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	439000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-480000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	439000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2040000	usd
CY2024	us-gaap	Depreciation Depreciation	1000	usd
CY2023	us-gaap	Depreciation Depreciation	3000	usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	85000	usd
CY2024	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	48000	usd
CY2024	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1148000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	16000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-38000	usd
CY2024	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-71000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-67000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-15000	usd
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	134000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-391000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	311000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-75000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-69000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	172000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-423000	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	11000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	161000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-423000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18000	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-480000	usd
CY2024Q2	CVAT	Working Capital WorkingCapital	-403000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26847000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zzFSBoF5VyZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><i><span id="xdx_86F_zXcnz35J9Ugh">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	1112000	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	9000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	44000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zZdoAJZ1X4kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><b><i><span id="xdx_860_zjvuzy1NuZCk">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>During the year ended June 30, 2024, we recorded <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zvzdp5IqjYAb" title="Concentration risk percentage">100</span>% of our revenue from Desmet Ballestra (Desmet). During the year ended June 30, 2023, we recorded <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zk2h7kT1FWKc" title="Concentration risk percentage">95</span>% of our revenue from Desmet and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EnviroWatertekLLCMember_zsAvKWpTj0Y3" title="Concentration risk percentage">5</span>% from Enviro Watertek, LLC (EW) (see Note 2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, three vendors accounted <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zX4xtSSqoN98">19</span>%, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_z42cl04lNxzi">15</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_z3rQcCg0ZvV9">11</span>% of the Company’s accounts payable. As of June 30, 2023, one vendor accounted <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zOEOJXBZ3Myc">38</span>% of the Company’s accounts payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>At June 30, 2024 and 2023, we had <span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_pp0p0_do_c20240630_zbzWFmZMSq43" title="Receivables from customers"><span id="xdx_905_eus-gaap--AccountsReceivableNet_iI_pp0p0_do_c20230630_z3rGYnnp8He1" title="Receivables from customers">no</span></span> receivables from our customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	1112000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1148000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	76000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	76000	usd
CY2024	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	78000	usd
CY2023	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	72000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.04	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.04	pure
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	113000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	46000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	121000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	47000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	47000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	46000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	524000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	524000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	524000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	523000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	usd
CY2024	us-gaap	Depreciation Depreciation	1000	usd
CY2023	us-gaap	Depreciation Depreciation	3000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	280000	usd
CY2024Q2	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	134000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	414000	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	5000	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	130000	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	145000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	139000	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	150000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	9000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	103000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	139000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	28841323	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y7M9D
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.08
CY2024Q2	CVAT	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber	28841323	shares
CY2024	CVAT	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisableWeightedAverageRemainingContractualTerm1	P2Y7M9D
CY2024	CVAT	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	-0.21	pure
CY2023	CVAT	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.07	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2024	CVAT	Effective Income Tax Rate Reconciliation Net Operating Loss Utilized EffectiveIncomeTaxRateReconciliationNetOperatingLossUtilized	-0.28	pure
CY2023	CVAT	Effective Income Tax Rate Reconciliation Net Operating Loss Utilized EffectiveIncomeTaxRateReconciliationNetOperatingLossUtilized	0	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.93	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.93	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.28	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10600000	usd
CY2024	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The Federal NOL carry forward of approximately $8.5 million expires through 2037, the remaining NOL of $2.1 million has no expiry date.
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2971000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3505000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	962000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	962000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3933000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4467000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3933000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4467000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-534000	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	466000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
cvat-20240630_cal.xml	Edgar Link	unprocessable
cvat-20240630_pre.xml	Edgar Link	unprocessable
0001683168-24-006768-index-headers.html	Edgar Link	pending
0001683168-24-006768-index.html	Edgar Link	pending
0001683168-24-006768.txt	Edgar Link	pending
0001683168-24-006768-xbrl.zip	Edgar Link	pending
cavitationlogo.jpg	Edgar Link	pending
cavitation_ex3101.htm	Edgar Link	pending
cavitation_ex3102.htm	Edgar Link	pending
cavitation_ex3201.htm	Edgar Link	pending
cavitation_ex3202.htm	Edgar Link	pending
cavitation_i10k-063024.htm	Edgar Link	pending
cvat-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
cvat-20240630_def.xml	Edgar Link	unprocessable
cvat-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cavitation_i10k-063024_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVAT
Cavitation Technologies, Inc. Stock $cvat

2024 Q3 Form 10-K Financial Statement

#000168316824006768 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVAT Cavitation Technologies, Inc. Stock $cvat

2024 Q3 Form 10-K Financial Statement

#000168316824006768 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVAT
Cavitation Technologies, Inc. Stock $cvat